Beijing Attracts Billion-Yuan Investment For Health Care Projects
This article was originally published in PharmAsia News
To accelerate the development of the biopharmaceutical industry, Beijing Municipal Bureau of Industrial Development is stepping up efforts to provide investors with policy consulting and tracking services. The city has this year signed up eight major health care investments totaling 3.83 billion yuan ($548 million). The projects comprise: (1) joint production of MMR (measles, mumps and rubella) vaccines by GSK and Xili Pharmaceutical Group; (2) Genzyme Biotech Beijing's R&D and laboratory production project; (3) Kaizheng Biotech's human blood substitutes and new drug R&D production base; (4) Xiuzheng Pharmaceutical Group's industrial park; (5) Korean Daewoong Pharmaceutical's R&D center and production base; (6) Tiandao Biotech's monoclonal antibody R&D and production base; (7) Mindray's Beijing academic institution; and (8) Genova Biotech's Novaferon production base. (Click here for more - Chinese language)
You may also be interested in...
SEOUL - South Korea's Daewoong Pharmaceutical opened a new research and development center Jan. 20 in the southern India city of Hyderabad as it tries to pave the way for the development of what it called "different generics" and new brand products for the U.S. and European markets
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.